Retatrutide

Retatrutide (LY3437943) is Eli Lilly's once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors, and the lead pivotal obesity readout has now landed. TRIUMPH-1 (NCT05929066, n=2,339, 80-week primary endpoint) reported in May 2026: mean body weight reductions of 19.0%, 25.9%, and 28.3% on 4 mg, 9 mg, and 12 mg respectively versus placebo [1][12]. That is the largest weight loss reported in a Phase 3 obesity pivotal to date, though direct comparators like Novo's amycretin are still generating Phase 3 data [13]. Phase 3 covers obesity (TRIUMPH), type 2 diabetes (TRANSCEND), chronic kidney disease, MASH (metabolic dysfunction-associated steatohepatitis, the current name for advanced fatty liver disease), and a 10,000-patient cardiovascular outcomes trial [2][3][4][5]. This is Lilly's swing at making tirzepatide look like a mid-generation drug, and the commercial stakes for a company with $65B in 2025 revenue are enormous [6].

Novel investigational compound, no approvals anywhere. Pivotal obesity readout in hand: TRIUMPH-1 (NCT05929066), the 2,339-patient placebo-controlled Phase 3 in obesity or overweight with a weight-related comorbidity, reported 28.3% mean weight loss at 80 weeks on 12 mg in May 2026 [12]. Lilly has stated it intends to file for regulatory approval on the obesity indication in 2026 based on TRIUMPH-1, with additional TRIUMPH pivotal readouts stacking through 2026-2027. The head-to-head study against Lilly's own tirzepatide (NCT06662383, n=800, active not recruiting) remains the most commercially loaded readout for positioning [7]. TRANSCEND-T2D-1 in adults with type 2 diabetes on diet and exercise alone was published in the Lancet in 2026 [2]. TRIUMPH-Outcomes (NCT06383390) is a 10,000-patient cardiovascular and kidney outcomes trial in obesity, active not recruiting, and will run for years [3]. SYNERGY-Outcomes (NCT07165028) is a Phase 3 MASH master protocol with 4,500 patients recruiting [4]. No public FDA breakthrough or fast track designation has been disclosed by Lilly for the obesity program. Lilly is pursuing biologic status for retatrutide, which would carry 12 years of regulatory exclusivity rather than the 5-year small-molecule window that applies to tirzepatide, materially shifting the commercial runway if granted [14]. Assume BLA (Biologics License Application, the FDA submission package for biologic approval) submission in the second half of 2026 for the lead obesity indication, with initial FDA action possible in 2027.

Retatrutide hits three gut and pancreas hormone receptors at once. GLP-1 (glucagon-like peptide 1) is the receptor that tirzepatide, semaglutide, and liraglutide all activate: it slows stomach emptying, blunts appetite in the brain, and improves insulin release. GIP (glucose-dependent insulinotropic polypeptide, historically called gastric inhibitory polypeptide) is the second receptor, added by tirzepatide. The renamed nomenclature reflects that GIP's dominant physiological role is triggering insulin release when glucose is present, not slowing the stomach. GIPR activation appears to amplify the GLP-1 effect on weight and glucose while softening nausea, though the biology is still contested [8]. The third receptor, glucagon (GCGR), is the new move. Glucagon usually raises blood sugar, which is why nobody wanted to hit it. But glucagon also burns energy in the liver and increases fat oxidation. Adding controlled GCGR agonism on top of GLP-1 and GIP appears to push weight loss beyond what dual agonism can do, at the cost of needing careful dose titration to keep glucose in range. The clinical dose escalation is slow (a 4 mg starting dose stepped up over months) which limits gastrointestinal tolerability failures but also constrains time-to-effect versus tirzepatide. Human proof is strong: the Phase 2 obesity data showed roughly 24% mean weight loss at 48 weeks on 12 mg [1] and the Phase 3 TRIUMPH-1 confirmed 28.3% at 80 weeks on 12 mg [12], and a 2026 network meta-analysis ranks retatrutide at the top of the pharmacotherapy field for weight reduction [9]. The mechanism is validated at the genetics and pharmacology level for GLP-1 and GIP, and now at the human clinical Phase 3 level for the triple.

The Phase 3 program is broad and well-resourced. The obesity flagship is TRIUMPH-1 (NCT05929066), a 2,339-patient placebo-controlled trial in adults with obesity or overweight plus one weight-related comorbidity, dosing 4, 9, and 12 mg once weekly with percent change in body weight at 80 weeks as the primary endpoint [12]. The most commercially informative single study is NCT06662383, an 800-patient head-to-head of retatrutide versus tirzepatide in adults with obesity, active not recruiting, with body weight percent change as primary [7]. TRANSCEND-T2D-3 (NCT06297603, n=320, active not recruiting) tests retatrutide versus placebo in type 2 diabetes with moderate to severe renal impairment on basal insulin, with HbA1c as the primary endpoint [10]. TRIUMPH-Outcomes (NCT06383390) is a 10,000-patient event-driven cardiovascular and kidney outcomes trial, active not recruiting, with composite MACE (major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack, or non-fatal stroke) endpoints [3]. SYNERGY-Outcomes (NCT07165028) is a 4,500-patient MASH master protocol using time to major adverse liver outcomes as primary [4]. The TRANSCEND-CKD rationale and design paper documents kidney outcome selection in that population [5]. Enrollment execution has been unusually clean for Lilly, most core studies are already active not recruiting, which cuts execution risk. The main design question resolved: TRIUMPH-1 read out clearly positive against placebo. The unresolved design question is whether NCT06662383 is powered to show clear superiority over tirzepatide on weight, not just non-inferiority. If it only ties, the premium pricing thesis dents.

Our model estimates a 34% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 66%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, a randomized design, and a comparator/control arm. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Safety is the headline risk. Adding glucagon receptor agonism raises three specific concerns: transient glucose elevation in non-diabetic patients, small resting heart rate increases seen in Phase 2, and unclear long-term effects on liver fat and lean mass. TRIUMPH-1 safety profile at 80 weeks looked broadly consistent with Phase 2, but the 10,000-patient TRIUMPH-Outcomes cardiovascular and kidney trial is where any real signal would emerge [3][12]. Efficacy risk on the head-to-head against tirzepatide is real: if retatrutide only matches tirzepatide in NCT06662383 rather than clearly beats it, the premium pricing thesis collapses and Lilly ends up with intra-portfolio cannibalization instead of a next-generation win [7]. Execution risk is low. Enrollment across the core program is already closed or advanced. Commercial risk is nontrivial even with a clean approval: payers are already fighting GLP-1 coverage, orforglipron (Lilly's own oral GLP-1) is coming, and Novo Nordisk's next-generation combinations are advancing. The most direct mechanistic competitor is amycretin, Novo's GLP-1 plus amylin dual agonist, which produced 22% weight loss at 36 weeks in Phase 1b/2a and entered Phase 3 in Q1 2026 [13]. Amycretin combines gut hormones through a different second axis (amylin from beta cells rather than glucagon from alpha cells), and its Phase 3 readouts will land later than retatrutide's, giving Lilly a first-mover window. Mazdutide, Innovent's GLP-1 plus glucagon dual agonist, is Phase 3 in China and represents the direct mechanistic pressure on the GCGR side [9]. A 2026 BMJ network meta-analysis puts retatrutide at the top of the weight-loss ranking, but the differential over tirzepatide in indirect comparisons is not massive [9]. Perceived patient benefits from the Phase 2 qualitative substudy were strong, which helps adherence economics [11]. Patent and exclusivity risk: Lilly is pursuing biologic classification, which would convert exclusivity from 5 to 12 years and materially reshape the commercial curve if granted [14].

Worth watching, one of the highest-signal pipeline assets in metabolic disease, and TRIUMPH-1 has already de-risked the primary obesity indication. The remaining flip point is the head-to-head result against tirzepatide (NCT06662383): a clean superiority readout on body weight percent change resets Lilly's obesity franchise for another five years and pressures Novo's amycretin program directly [7]. If it comes in as non-inferior only, retatrutide becomes a defensive line-extension rather than a franchise driver. Check back on the next two Lilly earnings calls for BLA timing and FDA feedback on biologic classification, and monitor the TRIUMPH-Outcomes CV/kidney trial for interim safety board disclosures, which would be the first place a glucagon-related signal surfaces [3][6]. TRANSCEND-T2D-1 publication in the Lancet in 2026 already de-risked the diabetes indication [2]. For a company with $65B in 2025 revenue, this asset is the difference between Lilly holding its obesity leadership through 2030 and being caught by Novo's amycretin and next-generation combinations. This is not investment advice.

Content is educational and reflects public trial data and analyst-style framing as of the generation date. Not investment advice.